Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa

References

• World Health Organization. Viral hepatitis: report by the Secretariat. 2010 Mar 25.
   Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012;57:167–85.
   PubMed Web of Science ®Google Scholar
• Lok A, McMahon B. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–3.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263–83.
   PubMed Web of Science ®Google Scholar
• Ayoub W, Keeffe E. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008;28:167–77.
   PubMed Web of Science ®Google Scholar
• Guan R. Treatment of chronic hepatitis B infection using interferon. Med J Malaysia 2005;60:28–33.
   PubMedGoogle Scholar
• Shiozawa H, Nishizaki Y, Motegi S, Kojima S, Watanabe N, Mine T. Non-response to previous interferon therapy and cirrhosis are risk factors for predicting breakthrough during lamivudine therapy in patients with chronic hepatitis B. Tokai J Exp Clin Med 2010;35:103–6.
   PubMedGoogle Scholar
• European Association For The Study Of The Liver. Management of treatment failure in chronic hepatitis B. J Hepatol 2012;56:S112–22.
   Google Scholar
• Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699–705.
   PubMed Web of Science ®Google Scholar
• Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428–34.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006;10:iii–v; xi-xiv, 1-183.
   PubMed Web of Science ®Google Scholar
• Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technol Assess 2009;13:1–172. iii.
   Web of Science ®Google Scholar
• Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14:1165–74.
   PubMed Web of Science ®Google Scholar
• Keating GM. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. Drugs 2009;69:2633–60.
   PubMed Web of Science ®Google Scholar
• Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients. J Gastrointestin Liver Dis 2009;18:425–31.
   PubMed Web of Science ®Google Scholar
• Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis 2011;11:165.
   PubMed Web of Science ®Google Scholar
• Kim BK, Han KH, Ahn SH. Hepatitis B virus serology to predict antiviral response in chronic hepatitis B. Digestion 2011;84:29–34.
   PubMed Web of Science ®Google Scholar
• Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005;41:1357–64.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wu YH, Shu ZY, Zhang WJ, Yang J, Chen Z. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials. Hepatobiliary Pancreat Dis Int 2010;9:462–72.
   PubMed Web of Science ®Google Scholar
• Akarca US, Ersoz G, Gunsar F, Karasu Z, Saritas E, Yuce G, Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 2004;9:325–34.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-alpha(2a) in clinical practice: how to manage patients suffering from side effects. Expert Opin Drug Saf 2011;10:429–35.
   PubMed Web of Science ®Google Scholar
• Shiga K, Tanaka E, Isayama R, Mizuno T, Itoh K, Nakagawa M. Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon alpha-2b: a neuropathology case report. Intern Med 2012;51:217–21.
   PubMed Web of Science ®Google Scholar
• Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14:1165–74.
   PubMed Web of Science ®Google Scholar
• Ingiliz P, Valantin MA, Thibault V, Duvivier C, Dominguez S, Katlama C, Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008;13:895–900.
   PubMed Web of Science ®Google Scholar
• Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008;2:304–7.
   PubMed Web of Science ®Google Scholar